Vascular risk equations are tools used to help prevent cardiovascular events. Our aim was to compare the REGICOR and SCORE equations in a general population and in persons with the metabolic syndrome (MS) according to the criteria of the International Diabetes Federation.
Methods and results
We calculated the cardiovascular risk with both equations in a random sample of 838 non-diabetic persons aged 40–65 years without a history of cardiovascular disease, of whom 251 had the MS. Of the 838 persons, 3.6% had a high risk according to SCORE and 1.5% according to REGICOR, and of these, 53.3% and 61.5%, respectively, had the MS. The mean risk was greater in the persons with the MS than those without (REGICOR 4.6% vs. 2.6% and SCORE 1.7% vs. 1%; p<0.01 for each). In comparison with the group without the MS, the percentage of persons with the MS who had a high risk was greater with both scales: REGICOR (3.2% vs. 0.8%, p=0.027) and SCORE (6.4% vs. 2.4%, p=0.004). The agreement (kappa index) classifying the subjects with a high risk, was 0.453 in the overall sample and 0.391 in the subgroup with the MS.
The percentage of persons classified as having a high cardiovascular risk differed between REGICOR and SCORE. Using these scales only a small percentage of non-diabetic persons with the MS have a high risk. The presence of the MS multiplies the percentage of non-diabetic persons with a high vascular risk two-fold with SCORE and four-fold with REGICOR.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Internal Medicine
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cardiovascular disease risk profiles.Am Heart J. 1991; 121: 293-298
- Prediction of coronary heart disease using risk factor categories.Circulation. 1998; 97: 1837-1847
- Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study.Eur Heart J. 2000; 21: 365-370
- Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in Gerona, Spain, 1990–1992.Int J Epidemiol. 1998; 27: 599-604
- Coronary risk estimation in Spain using a calibrated Framingham function.Rev Esp Cardiol. 2003; 56: 253-261
- Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.Eur Heart J. 2003; 24: 987-1003
- Spanish adaptation of the European guidelines on cardiovascular disease prevention.Rev Esp Salud Publica. 2004; 78: 435-438
- The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation.Diabetologia. 2010; 53: 600-605
- Metabolic syndrome: cardiovascular risk assessment and management.Am J Cardiovasc Drugs. 2007; 7: 259-272
- Global coronary heart disease risk assessment of individuals with the metabolic syndrome in the U.S.Diabetes Care. 2008; 31: 1405-1409
- ESC/EAS guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Atherosclerosis. 2011; 217: 3-46
- Hypertriglyceridemic waist: an alternative to the metabolic syndrome? Results of the IMAP Study (Multidisciplinary Intervention in Primary Care).Int J Obes. 2011; 35: 292-299
- The IDF consensus worldwide definition of the metabolic syndrome.(Available in:)[14 June 2008])
- Visceral obesity and metabolic syndrome: two faces of the same medal?.Intern Emerg Med. 2010; 5: 111-119
- Comparison of the REGICOR and SCORE function charts for classifying cardiovascular risk and for selecting patients for hypolipidemic or antihypertensive treatment.Rev Esp Cardiol. 2007; 60: 139-147
- Comparison of the SCORE and REGICOR models for calculating cardiovascular risk in cardiovascular disease-free individuals at a healthcare center in Barcelona, Spain.Rev Esp Salud Publica. 2005; 79: 453-464
- New instruments, same risks.Rev Esp Cardiol. 2007; 60: 464-467
- Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP).JAMA. 2001; 285: 2486-2497
- Validation of 3 equations of coronary risk in diabetic population of a primary care center.Med Clin (Barc). 2006; 126: 485-490
- Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes.Diabetes Care. 2007; 30: 1292-1294
- Comparison of the SCORE function chart and the Framingham-REGICOR equation to estimate the cardiovascular risk in an urban population after 10 years of follow-up.Med Clin (Barc). 2006; 127: 368-373
- Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.Arterioscler Thromb Vasc Biol. 2008; 28: 1039-1049
- Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome.Diabetes Care. 2005; 28: 1769-1778
- Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults.Circulation. 2004; 110: 1245-1250
- Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men.Circulation. 2010; 121: 230-236
- The application of the SCORE charts to advanced age males triple the number of high-risk subjects compared to the Framingham function.Med Clin (Barc). 2005; 124: 487-490
- The metabolic syndrome is not a sensible tool for predicting the risk of coronary heart disease.Eur J Cardiovasc Prev Rehabil. 2009; 16: 210-214
Published online: March 26, 2012
Accepted: February 27, 2012
Received in revised form: February 8, 2012
Received: November 27, 2011
© 2012 European Federation of Internal Medicine. Published by Elsevier Inc. All rights reserved.